Search
Eritoran
go.drugbank.com/drugs/DB04933InvestigationalEritoran is a structural analogue of the lipid A portion of lipopolysaccharide (LPS). It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.
Col-118
go.drugbank.com/drugs/DB05778InvestigationalIt is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue. … Col-118 is a unique formulation and presentation of Brimonidine, which is a selective alpha-2 adrenergic receptor agonist.
Cyanocobalamin Co-60
go.drugbank.com/drugs/DB09387ApprovedWithdrawnCyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons. … Cyanocobalamin Co-60 is an analog of Vitamin B12 labeled with Co60.
Fluoride ion
go.drugbank.com/drugs/DB11257ApprovedInvestigationalHaving a chemical formula of F−, fluoride ion is the simplest inorganic, monatomic anion of fluorine with basic properties. It is considered a trace element. … Fluoride ions are found in various minerals but are only present in trace amounts in water.
Mixtures: ADDAMEL NSynonyms: Fluoride ionTalampanel
go.drugbank.com/drugs/DB04982InvestigationalTalampanel is a substance that is being studied in the treatment of brain tumors and other brain disorders, such as epilepsy and Parkinson disease. It is a type of AMPA receptor antagonist.
Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins
go.drugbank.com/drugs/DB15729InvestigationalLipoaspiration, also known as liposuction, is a possible method for extraction. This is followed by purification and expansion of the cells in vitro. … This explains why AMSCs have been utilized in repairing craniofacial bone defects. They also have potential in treatment of scarred vocal folds.
SR 121463
go.drugbank.com/drugs/DB05455InvestigationalIt is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH). … SR 121463 is a nonpeptide aquaretic compound with potent selective antagonism of the vasopressin V2 (V1b) receptor subtype.
D-JNKI-1
go.drugbank.com/drugs/DB05660InvestigationalA synthetic, cell permeable peptide that blocks the MAPK-JNK signal pathway; has potential therapeutic value for long-term protection of both the morphological integrity and physiological function of the
Levilimab
go.drugbank.com/drugs/DB16387InvestigationalLevilimab is under investigation in clinical trial NCT04227366 (Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis).